Polar Capital Holdings Plc Sells 11,052 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Polar Capital Holdings Plc decreased its position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 7.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 142,900 shares of the medical device company's stock after selling 11,052 shares during the quarter. Polar Capital Holdings Plc owned 0.22% of Tandem Diabetes Care worth $5,147,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. lifted its position in Tandem Diabetes Care by 1.1% in the fourth quarter. Vanguard Group Inc. now owns 7,440,005 shares of the medical device company's stock valued at $267,989,000 after purchasing an additional 77,451 shares during the last quarter. ArrowMark Colorado Holdings LLC raised its holdings in shares of Tandem Diabetes Care by 14.1% during the fourth quarter. ArrowMark Colorado Holdings LLC now owns 2,723,715 shares of the medical device company's stock valued at $98,108,000 after acquiring an additional 337,026 shares in the last quarter. GW&K Investment Management LLC raised its holdings in shares of Tandem Diabetes Care by 18.0% during the fourth quarter. GW&K Investment Management LLC now owns 2,123,488 shares of the medical device company's stock valued at $76,488,000 after acquiring an additional 323,674 shares in the last quarter. Jacobs Levy Equity Management Inc. raised its holdings in shares of Tandem Diabetes Care by 189.0% during the fourth quarter. Jacobs Levy Equity Management Inc. now owns 1,661,013 shares of the medical device company's stock valued at $59,830,000 after acquiring an additional 1,086,337 shares in the last quarter. Finally, Park West Asset Management LLC raised its holdings in shares of Tandem Diabetes Care by 49.5% during the fourth quarter. Park West Asset Management LLC now owns 1,600,000 shares of the medical device company's stock valued at $57,632,000 after acquiring an additional 530,000 shares in the last quarter.

Tandem Diabetes Care Stock Down 4.4%

Shares of NASDAQ TNDM traded down $1.04 during trading on Wednesday, reaching $22.49. The company had a trading volume of 356,449 shares, compared to its average volume of 1,499,748. Tandem Diabetes Care, Inc. has a 12-month low of $15.75 and a 12-month high of $53.69. The stock has a market cap of $1.50 billion, a PE ratio of -11.65 and a beta of 1.47. The business's 50-day moving average is $19.31 and its 200 day moving average is $27.72. The company has a quick ratio of 2.32, a current ratio of 2.90 and a debt-to-equity ratio of 1.29.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The medical device company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.07). Tandem Diabetes Care had a negative net margin of 14.84% and a negative return on equity of 44.19%. The business had revenue of $234.42 million for the quarter, compared to analysts' expectations of $220.19 million. During the same period last year, the business earned ($0.65) earnings per share. The company's quarterly revenue was up 22.3% on a year-over-year basis. As a group, equities analysts forecast that Tandem Diabetes Care, Inc. will post -1.68 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, COO Jean-Claude Kyrillos acquired 10,538 shares of the firm's stock in a transaction dated Friday, March 7th. The shares were purchased at an average price of $18.12 per share, with a total value of $190,948.56. Following the completion of the purchase, the chief operating officer now directly owns 10,538 shares of the company's stock, valued at $190,948.56. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 1.90% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on TNDM. The Goldman Sachs Group decreased their target price on Tandem Diabetes Care from $42.00 to $24.00 and set a "neutral" rating for the company in a report on Monday, March 3rd. Sanford C. Bernstein cut Tandem Diabetes Care from an "outperform" rating to a "market perform" rating and reduced their price target for the stock from $35.00 to $25.00 in a research note on Friday, February 28th. Stifel Nicolaus reduced their price target on Tandem Diabetes Care from $60.00 to $31.00 and set a "buy" rating on the stock in a research note on Thursday, May 1st. Barclays reduced their price target on Tandem Diabetes Care from $60.00 to $53.00 and set an "overweight" rating on the stock in a research note on Friday, February 28th. Finally, Robert W. Baird reduced their price target on Tandem Diabetes Care from $33.00 to $24.00 and set a "neutral" rating on the stock in a research note on Thursday, May 1st. Eight analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $39.81.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.